Monitoring neuroprotection and restorative therapies in Parkinson’s disease with PET
In this article the role of functional imaging (PET and SPECT) as a surrogate marker for following the progression of Parkinson’s disease (PD) is discussed. The potential value of PET and SPECT for assessing the efficacy of putative neuroprotective agents in PD is considered and a review of 18F-dopa PET findings in transplantation trials involving implantation of human and procine fetal mesencephalic tissue is presented. It is concluded that functional imaging provides a valuable adjunct to clinical assessment when judging the efficacy of neuroprotective and restorative approaches to PD.
KeywordsPositron Emission Tomography Multiple System Atrophy Restorative Therapy Dopa Positron Emission Tomography Nigral Cell Loss
Unable to display preview. Download preview PDF.
- Alexander T, Sortwell CE, Sladek CD, Roth RH, Steece-Collier K (1997) Comparison of neurotoxicity following repeated administration of L-dopa, D-dopa, and dopamine to embryonic mesencephalic dopamine neurons in cultures derived from Fischer 344 and Sprague-Dawley donors. Cell Transplant 6: 309-315PubMedCrossRefGoogle Scholar
- Banati R, Cagnin A, Myers R et al (1999b) In vivo detection of activated microglia by ["C]PK11195-PET indicates involvement of the globus pallidum in idiopathic Parkinson’s disease. Parkinsonism Relat Disord 5: S56 (abstr)Google Scholar
- Brundin P, Pogarel O, Hagell P et al (2000) Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson’s disease. Brain (in press)Google Scholar
- Fahn S, Elton RL, and members of the UPDRS development committee (1987) Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Goldstein M et al (eds) Recent developments in Parkinson’s disease. Macmillan, New York, 153-163Google Scholar
- Jellinger K (1987) The pathology of parkinsonism. In: Marsden CD, Fahn S (eds) Movement disorders 2. Butterworths, London, 33-65Google Scholar
- Leber P (1997) Slowing the progression of Alzheimer disease: Methodologic issues. Alzheimer Dis Assoc Disord 11 Suppl 5: S10-S20Google Scholar
- Marek KL, Innis RB, Seibyl J (1998) Assessment of Parkinson’s disease progression with 3-CIT and SPECT imaging. Mov Disord 13 Suppl 2: 238 (abstr)Google Scholar
- Nurmi EM, Ruottinen HM, Bergman J, Haaparanta M, Solin O, Rinne JO (1999) The rate of progression in Parkinson’s disease: A [18F]Dopa PET study. Neurology 52 Suppl 2: A91 (abstr)Google Scholar
- Olanow CW, Jenner P, Brooks D (1998) Dopamine agonists and neuroprotection in Parkinson’s disease. Ann Neurol 44 Suppl 1: S167-S174Google Scholar
- Rakshi JS, Bailey DL, Morrish PK, Brooks DJ (1996) Implementation of 3D acquisition, reconstruction, and analysis of dynamic [18F] Fluorodopa studies. In: Myers R, Cunningham V, Bailey D, Jones T (eds), Quantification of brain function using PET. Academic Press, San Diego, 82-87CrossRefGoogle Scholar